Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.transpact.in | |
Market Cap | 12.67 Cr. | |
Enterprise Value(EV) | 12.69 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -1.70 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-03 |
Industry PE | 62.13 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 13.79 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 23.75 | Calculated using Price: 327.50 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 0.04 Cr. | 386,730 Shares |
FaceValue | 10 | |
About Transpact Enterprises Ltd. | ||
Transpact Enterprises, Maharashtra based is a biotechnology startup. It provides comprehensive & cost-effective products and solutions to specially-abled people. The company is continuously working towards technological innovations and interventions to improve their products. Transpact Enterprises mainly designs, develops and distributes Vestibulator, a therapeutic device. The device has been invented by the Society for Innovation and Entrepreneurship, lIT Bombay. And, Transpact Enterprises holds a license to carry out the commercial activities of Vestibulator. It is a co-patented technology of the company and IRCC-IIT Bombay. The company outsources the manufacturing of the device along with the design details to a 3rd party. With the help of advanced software, the company also offers customized device solutions for patients. |
1 Day |
|
|
1 Week |
|
-1.21% |
1 Month |
|
+28.48% |
3 Month |
|
+117.25% |
6 Month |
|
+110.75% |
1 Year |
|
+146.24% |
2 Year |
|
+112.66% |
5 Year |
|
|
10 Year |
|
7 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -27.59 | -77.28 | -804.02 | -97.83 | -7.53 | -31.12 | -11.64 | |
Return on Capital Employed (%) | -19.45 | -27.62 | -66.20 | -53.57 | -5.23 | -21.88 | -7.88 | |
Return on Assets (%) | -19.19 | -25.93 | -60.34 | -47.48 | -4.78 | -17.80 | -6.14 |
Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | |
Non Curr. Liab. | 0 | 0 | 0 | 0 | 0 | 0 | |||
Curr. Liab. | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
Minority Int. | |||||||||
Equity & Liab. | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
Non Curr. Assets | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | |
Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Misc. Exp. not W/O | |||||||||
Total Assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 0 | 0 | 0 | 0 | ||||
Other Income | 0 | 0 | 0 | |||||
Total Income | 0 | 0 | 0 | 0 | 0 | |||
Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | ||||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | |||
Taxation | 0 | 0 | 0 | |||||
Exceptional Items | ||||||||
PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Adjusted EPS | -2 | -3 | -11 | -11 | -2 | -6 | -2 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | -1 | 0 | -1 | 0 | |
Cash Fr. Inv. | 0 | 0 | 0 | |||||
Cash Fr. Finan. | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
Net Change | 0 | 0 | 0 | -1 | 0 | |||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | -1 | 0 |
Mon, 13 Nov 2023
Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2023 Outcome of Board Meeting & Submission of Unaudited Financial Results for Half Year ended September 30 2023. |
Mon, 13 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2023 In continuation of our letter dated November 06 2023 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2023 duly approved by the Board of Directors of the Company in their meeting held today i.e. November 13 2023 |
Tue, 07 Nov 2023
Announcement Under Regulation 30 Of SEBI(LODR) 2015-Reconstitution Of The Committees Of The Board Of Directors. Reconstitution of Committee of Board of Directors |
Tue, 05 Dec 2023 |
|
|
|
|
|